Origami Therapeutics is collaborating with Ipsen to develop experimental therapies designed to remove or correct abnormal proteins that build up in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The partnership will focus on small molecules known as protein degraders and correctors. These compounds are designed to…
Search results for:
Coya Therapeutics has raised about $11.1 million in a private investment round to support commercial-readiness efforts for COYA 302, its experimental immune-modulating therapy being developed for amyotrophic lateral sclerosis (ALS). The funding was secured through the sale of more than 2.5 million company shares to two investors, the company…
A bipartisan team of U.S. lawmakers has reintroduced the ALS Better Care Act, a bill that aims to improve access to quality medical care for people with amyotrophic lateral sclerosis (ALS). The legislation was introduced in the House by Republican Brian Fitzpatrick of Pennsylvania and Democrats Jason Crow…
Patient enrollment has reached the halfway mark in an ongoing expanded access program (EAP) for MN‑166 (ibudilast), Medicinova’s oral anti-inflammatory drug for the treatment of amyotrophic lateral sclerosis (ALS). EAPs, also known as compassionate use programs, are designed to help people with serious or life-threatening diseases receive experimental…
In the U.S., clinical trials for amyotrophic lateral sclerosis (ALS) do not include enough non-white patients and women to fully represent the disease’s landscape in the real world, a study found. This lack of representation of certain groups may prevent researchers from generalizing clinical trial findings to the overall…
Smoking is a risk factor for developing amyotrophic lateral sclerosis (ALS) and can worsen symptoms for those already living with the disease. While ALS is progressive, quitting smoking can offer real benefits, including a lower risk of lung infections and a slower decline in breathing function. Understanding…
Scientists have developed a way to grow motor neurons, the highly specialized nerve cells that are lost in amyotrophic lateral sclerosis (ALS), opening the door to new research avenues for treatment discovery. The new approach directs rare adult brain progenitor cells to become corticospinal-like neurons, a type of nerve…
A viral infection can trigger a neurological disease similar to amyotrophic lateral sclerosis (ALS) in mice with a specific genetic profile, providing evidence for how genetics and environment may interact to cause the disorder, according to a new study. Findings suggest that while a virus may be…
Partially lowering levels of the protein RAD23A can help nerve cells better handle toxic TDP-43 protein clumps, improving survival and function in a mouse model of amyotrophic lateral sclerosis (ALS), a study found. The approach reduced the buildup of misfolded proteins, restored the cell’s protein cleanup machinery, and slowed…
For many people with amyotrophic lateral sclerosis (ALS), even a slight slowing of disease progression is considered clinically meaningful, according to a new study based on a survey of hundreds of patients. “These results highlight the need for clinical trial designs that are capable of detecting small but meaningful…